Drugs / SY-5933
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06006793 | Aug 2023 → Feb 2025 | neoplasm | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06970132 | Jun 2025 → Dec 2027 expected | — | Shouyao Holdings (Beijing) Co. LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-5933 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06006793 ↗ |
| Action | Inhibit | “KRAS p.G12C inhibitor” NCT06006793 ↗ |
| Route | Oral | “SY-5933 tablets QD, oral administration” NCT06006793 ↗ |
| Target | KRAS | “KRAS p.G12C inhibitor” NCT06006793 ↗ |